No open-market buying or selling by insiders.
The last open-market buy by an executive or director was in May 2025.
Get an email when JBIO's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| May 16, 2025 | Tom Frohlich Chief Executive Officer | Bought | 6,000 | $7.40 | 44K | New | Form 4 |
- May 16, 2025Tom FrohlichChief Executive Officer · bought 6,000 at $7.4044KNew position
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with JBIO
Held by ETFs
JBIO is in 16 US ETFs. The largest of them, with JBIO's weight in each:
Vanguard Health Care ETFVHT0.01%of the fund
iShares Russell 2000 Growth ETFIWO0.04%of the fund
Fidelity Nasdaq Composite Index ETFONEQ0.01%of the fund
State Street SPDR S&P Biotech ETFXBI0.24%of the fund
Fidelity MSCI Health Care Index ETFFHLC0.01%of the fund
Avantis U.S. Small Cap Equity ETFAVSC0.04%of the fund
Spot a number that looks wrong? Check it in JBIO's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing JBIO
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.